Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.49 |
| ▸ | PGK1 | P00558 | 5/20 | 0.48 |
| ▸ | PGK2 | P07205 | 5/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8363191 | 0.82 | ENPP2 (0.42) | ENPP2PTGS2EPHX2NR1H4GRM4 | |
| SCHEMBL12931440 | 0.81 | ENPP2 (0.45) | ENPP2PTGS2EPHX2NR1H4GRM4 | |
| SCHEMBL6182058 | 0.80 | ENPP2 (0.41) | ENPP2PTGS2EPHX2NR1H4 | |
| SCHEMBL6184850 | 0.80 | ENPP2 (0.43) | ENPP2PTGS2EPHX2NR1H4 | |
| SCHEMBL1617420 | 0.80 | PGK1 (0.67) | ENPP2PGK1PGK2DGAT2 | |
| SCHEMBL915493 | 0.77 | PGK1 (0.46) | ENPP2PGK1PGK2 | |
| SCHEMBL3166623 | 0.77 | HTR6 (0.53) | PGK1PGK2 | |
| SCHEMBL6182049 | 0.77 | PTGS2 (0.43) | ENPP2PTGS2EPHX2NR1H4 | |
| SCHEMBL6839967 | 0.75 | ENPP2 (0.52) | ENPP2PTGS2EPHX2NR1H4 | |
| SCHEMBL1575569 | 0.74 | NPY5R (0.40) | ENPP2PTGS2EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156877-B2 | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzylidene derivatives, methods for the production thereof and use thereof for treating diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-13 | — | — | US | disclosed |
| US-20120316145-A1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-BENZYLIDENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-12-13 | — | — | US | disclosed |
| US-6919353-B2 | Substituted 8-arylquinolune PDE4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2005-07-19 | — | — | US | disclosed |
| EP-1404330-B1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-06-01 | — | — | EP | disclosed |
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2004-08-19 | — | — | US | disclosed |
| EP-1404330-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-04-07 | — | — | EP | disclosed |
| US-6572986-B2 | Subjecting the phosphor, the organic phosphorus compound, and a polyurethane binder to dispersing processing in order to prepare a coating mixture, applying the coating on a substrate to form phoshor layer | FUJI PHOTO FILM CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| WO-2003002118-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-01-09 | — | — | WO | disclosed |
| US-20010053461-A1 | Radiation image storage panel and process for producing the same | FUJIFILM CORPORATION (JP) | 2001-12-20 | — | — | US | disclosed |
| US-6099895-A | PHOSPHONIC ACID SURFACE MODIFYING COMPOUND | IMATION CORP. (US) | 2000-08-08 | — | — | US | disclosed |
| US-5868959-A | MAGNETIC PIGMENT HAVING ARALKYL PHOSPHONIC ACID ADSORBED ONTO SURFACE; HIGH SATURATION MAGNETIZATION AND HIGH SURFACE AREA | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| CN-1170151-A | Surface modification of magnetic particle pigments | MINNESOTA MINING & MFG (US) | 1998-01-14 | — | — | CN | disclosed |
| US-5501821-A | OPTICAL ARTICLES FOR TRANSMISSION OF ELECTROMAGNETIC WAVES WITH DIPOLES | EASTMAN KODAK COMPANY (US) | 1996-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | PDE12, PDE4A, PDE4B | ENPP2 941/4885PGK1 1981/4885PGK2 2430/4885 |
| US-20120316145-A1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-BENZYLIDENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | HSD17B11, CYP17A1, CYP19A1 | ENPP2 881/4885PGK1 3755/4885PGK2 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.